The world's first and leading photonic computing chip company, driving Moore's Law into the 2.0 era. Its core technology was pioneered by a team of scientists from the Massachusetts Institute of Technology (MIT), focusing on a matrix processor based on silicon photonics technology, which handles large-scale matrix multiplication tasks in deep learning. Compared to traditional electronic chips, it achieves a 1000-fold increase in computational power while reducing energy consumption to one percent. The research findings were published in the photonics section of the journal Nature and featured on the homepage of the MIT official website for three consecutive days. It was hailed by the magazine Science as "illuminating the future of artificial intelligence." In May 2018, the company received a seed round investment of $300,000, with a post-investment valuation of $27 million. In early 2022, it completed a Series B financing round worth hundreds of millions of dollars at a valuation of $800 million, with Sequoia China leading the investment. Previous investors include Matrix Partners China, China Renaissance, CICC Capital, Tsingyuan Ventures, Tencent, Hillhouse Capital, Deep Ventures, Wuyuan Capital, and China Merchants Capital, among other top-tier institutions. The valuation increased by 29.6 times.

biotechnology company dedicated to solving the challenges associated with the use of nitrogen fertilizers. Founded by top Harvard professor Daniel Nocera, the company applies microbial charging technology to agriculture. The biologically produced fertilizers theoretically offer lower costs and can completely replace synthetic nitrogen fertilizers, while achieving negative carbon emissions throughout the production and application process. Daniel is a member of both the National Academy of Sciences and the National Academy of Engineering, and is a prominent figure in the field of chemistry. He successfully created the first "artificial leaf" and established a liquid battery company, which was acquired by Lockheed Martin for hundreds of millions of dollars. He has published 278 highly cited articles in top journals such as Nature, Science, PNAS, and other leading publications in the field of chemistry, totaling over 450 publications. Named one of Time magazine's 100 most influential people in 2009, he has been featured on the cover of Time magazine twice. The company's Series A financing round valued it at $210 million, marking a twelvefold increase in valuation.

Based on cutting-edge third-generation microfluidic technology patents from the United States, Professor David Weitz of Harvard University, along with Dr. Pei Hao, Dr. Liu Han, and Dr. Zheng Wenshan, founded Mozhuo Biotech in 2019, which settled in Zhejiang in 2020. Weitz's lab has also spawned companies such as Capsum (acquired by Chanel), RainDance (acquired by Bio-Rad for $87 million), and GnuBio (acquired by Bio-Rad for $50 million). Mozhuo possesses a world-leading microfluidic technology platform and has rich technical accumulation in single-cell sequencing. It has become a leader in the field of in vitro diagnostics and scientific research platforms and solutions, driven by microfluidic technology, biochemical technology, hardware development technology, and bioinformatics technology, supported by digital PCR technology platforms and single-cell sequencing platforms, and advancing in liquid biopsy, companion diagnostics, and life science research in parallel. In September 2021, it completed a Series A financing round led by Huagai Capital, with participation from Source Code Capital and Bilin Star Ventures, raising 150 million yuan (approximately $23.4 million), with a post-investment valuation of $120 million, marking a 21.8-fold increase from the investment.

The company won the championship in the national final of the Disruptive Innovation Competition, drafted China's first organ chip standard (skin) which passed the project approval announcement. Collaborating with a pharmaceutical factory, the company formally submitted Pre-IND using data from the Aiwei Organ Chip. The company's valuation increased from 300 million to 600 million RMB.

An outstanding enterprise in the field of rapid biological testing, it achieved the first prize in the Biomedicine category of the 2022 Shenzhen Innovation and Entrepreneurship Competition

a leading entity in breast cancer radiotherapy, positions itself as a comprehensive solution provider in the precision radiotherapy market. It has obtained certification from the U.S. FDA and European CE, with its products commencing overseas sales.

The in vitro micro-physiological system/organ chip technology system and products establish an innovative model for life science research. The company received the Outstanding Award at the National Final of the China National Innovation Competition.

Leading the way in non-invasive blood glucose detection, the company has obtained the national Class II medical device registration certificate in China.